Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy

Abstract

Normal serum D28-NSE is a strong, independent early predictor of both complete response to therapy and survival. This simple tool may be proposed for use in the clinic and in research, in association with an assessment of disease extension and performance status, to predict the outcome of patients with SCLC.

Survival in small cell lung cancer in India: Prognostic utility of clinical features, laboratory parameters and response to treatment

“…[ 25] As observed in previous studies, females survived longer than males, although this difference was not statistically important. [3,28] The prognostic significance of pre-treatment KPS is well known.…”

“…[3,7,8,23,24] In spite of the overall lower mean age, the proportion of patients presenting with extensive disease was higher than that reported in previous trials. [17,25] This could be attributed to (a) patient delay with a long interval between onset of the first symptom and seeking medical care due to ignorance about the disease, presence of other background symptoms, poor socio-economic status and lack of access to qualified health care professionals and specialized facilities (especially in far-flung geographical locales), (b) delay in diagnosis with a long interval between first presentation and confirmation of diagnosis due to high prevalence of other diseases, notably tuberculosis, which presents with similar symptoms (hence considerably diluting the clinical suspicion of malignancy) and (c) delay in treatment initiation (possibly due to high patient burden, limited centers offering oncology care and patient's inability to afford chemotherapy), allowing a considerably time for stage migration due to exponential growth of tumors. Western literature estimates that the median delay time in non-small cell lung cancer from onset of symptoms to initiation of treatment, is 4.6 months (3.4 months for advanced stage IV), whereas the median in-hospital delay (time of first hospital visit to start of treatment), is 1.6 month.…”

Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer

“…These prognostic markers are associated with overall survival (OS) in SCLC8910. Of the prognostic factors, PS and disease stage are important prognostic indicators for SCLC1112.…”

A Population Pharmacodynamic Model for Lactate Dehydrogenase and Neuron Specific Enolase to Predict Tumor Progression in Small Cell Lung Cancer Patients

“…ROC curves (i.e., true positive rate (sensitivity) vs. false positive rate (100-specificity)) for discriminating observed disease progression with simulated biomarker changes. Solid lines correspond to ROC curves, and the shaded area represents the confidence intervals obtained with bootstrapping predictions yielded contradictory conclusions [27][28][29][30][31][32][33][34][35]. These contradictions may have resulted from the use of empirical data analysis.…”